Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Mekinist
Trametinib is a kinase inhibitor indicated for the treatment of various cancers, including melanoma, non-small cell lung cancer, and thyroid cancer. It specifically targets the mitogen-activated protein kinase kinases MEK1 and MEK2, which are key components of the RAS/RAF/MEK/ERK signaling pathway often dysregulated in cancer. By inhibiting MEK, trametinib helps to slow or stop the growth and spread of cancer cells.
For the treatment of melanoma, non-small cell lung cancer, and thyroid cancer harboring specific genetic mutations.
Can cause severe or fatal heart failure, bleeding problems, eye problems, skin reactions, and lung or breathing problems. Can harm an unborn baby.
Outcome:
Decreased trametinib levels
Mechanism:
Induction of CYP3A4
Outcome:
Increased digoxin levels
Mechanism:
P-gp inhibition
Outcome:
Potential decreased trametinib absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: combination therapy with other targeted agents (2025, 85% confidence)
Based on current usage trends and clinical trial results, there is a 70% likelihood of trametinib being approved for additional cancer indications within the next 5 years.
Antineoplastic Agent, Kinase Inhibitor
Pyrimidinyl-imidazole